Enough for Sleepless of Shorts: "DMC’s interim analysis of efficacy data remains outstanding" __ Any Time From Now To ASCO
From 10k dated 1 April 2014:
"In December 2013, we announced that the number of events required to trigger the first interim analysis of the Phase III clinical trial had been reached. This milestone is measured by "events," which are defined as either a tumor recurrence or a death. With the current trial size, the pre-specified trigger number for the first interim analysis is 66 such events, comprising 60% of the 110 events required to reach the primary endpoint of the Phase III trial. The interim analysis will be conducted by an independent Data Monitoring Committee, or DMC, with assistance from the independent clinical research organization, or CRO, managing the trial. In March 2014, we announced that the DMC has conducted a review of the safety data, and recommended that the trial continue as planned. As we also announced the DMC’s interim analysis of efficacy data remains outstanding. With the current trial size, a second interim analysis will occur when 88 events, comprising 80% of the total 110 events, have been reached."
Plus DCVax-Direct "cancer shrinking and killing data that will be presented in ASCO in May/June;
Plus DCVax-L prostate cancer partnership deal -- anytime?
Plus other EU countries approval of DCVax-L for treating all forms of brain cancers